Literature DB >> 14399261

The endocrine eye lesion in hyperthyroidism. Its incidence and course in 165 patients treated for thyrotoxicosis with iodine.

H E HAMILTON, R O SCHULTZ, E L DE GOWIN.   

Abstract

Entities:  

Keywords:  EXOPHTHALMOS/etiology; HYPERTHYROIDISM/complications

Mesh:

Substances:

Year:  1960        PMID: 14399261

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


× No keyword cloud information.
  8 in total

1.  EFFECT OF THROXINE ON EXOPHTHALMOS IN THYROTOXICOSIS.

Authors:  D A KOUTRAS; W D ALEXANDER; W W BUCHANAN; R M HARDEN; R D HUNTER
Journal:  Br Med J       Date:  1965-02-20

2.  EFFECT OF TREATMENT OF THYROTOXICOSIS ON EXOPHTHALMOS.

Authors:  W R GREIG; S A ABOUL-KHAIR; S D MOHAMED; J CROOKS
Journal:  Br Med J       Date:  1965-08-28

3.  Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine.

Authors:  A Barth; P Probst; H Bürgi
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

4.  Observations on the course of exophthalmos after 131-I therapy.

Authors:  D I Jones; D S Munro; G M Wilson
Journal:  Proc R Soc Med       Date:  1969-01

5.  Thyroid disease and glaucoma.

Authors:  H Cheng; E S Perkins
Journal:  Br J Ophthalmol       Date:  1967-08       Impact factor: 4.638

Review 6.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

7.  The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.

Authors:  G B Bartley
Journal:  Trans Am Ophthalmol Soc       Date:  1994

Review 8.  Relationship between management of hyperthyroidism and course of the ophthalmopathy.

Authors:  L Bartalena; M L Tanda; E Piantanida; A Lai; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.